More Post from the Author
- FinVolution Group Announces New Share Repurchase Program of Up to US$150 million
- Le Costa Rica redouble ses efforts de promotion des investissements en Europe dans les secteurs des technologies agricoles, des services mondiaux et des infrastructures touristiques
- Modular Building Institute Names Matt Slataper President of the Board of Directors
- ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
- AARP Mississippi Applauds Passage and Signing of law to Protect Consumers from Cryptocurrency Kiosk Fraud
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- FinVolution Group Announces New Share Repurchase Program of Up to US$150 million
- Le Costa Rica redouble ses efforts de promotion des investissements en Europe dans les secteurs des technologies agricoles, des services mondiaux et des infrastructures touristiques
- Modular Building Institute Names Matt Slataper President of the Board of Directors
- ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
- AARP Mississippi Applauds Passage and Signing of law to Protect Consumers from Cryptocurrency Kiosk Fraud